Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA.

Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies. Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors.

Beijing Juete Biotechnology Co., Ltd., established on 2011-09-22, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Drug retail;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Abiogen Pharma is a pharmaceutical company that conducts research and development, manufactures pharmaceuticals under its own brand or under third-party contracts, and markets its own and licensed drugs. Its therapeutic areas of interest include bone metabolism, pain management, respiratory, metabolic (diabetes), and dermatological disorders.

Guangzhou Enbao Biomedical Technology Co., Ltd., established on 2012-04-25, Business scope includes engineering and technology research and experimental development;Natural science research and experimental development;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;Manufacturing of bio-based materials;Sales of bio-based materials;

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Shenzhen Tianda Kang Genetic Engineering Co., Ltd., established on 2001-11-22, Business scope includes general business items:Gene Therapy Drug Research,to develop,and related technical advice,Technical service and own technology transfer(No country restrictions,Prohibited items).,The licensing program is:

The Carlos III Health Institute (Spanish: Instituto de Salud Carlos III; ISCIII) is a Spanish public health research institute, legally constituted as a public research agency (Spanish: Organismo Público de Investigación), a type of quasi-autonomous entity under Spanish law. The agency is integrated in the Department of Science and Innovation, although it also reports to the Department of Health in the institute's activities relating health, healthcare and its planning.

CanSino Biologics, Inc. engages in the research and development, manufacturing, and sale of vaccines. It offers shingles, meningitis, polio, adenovirus, and tuberculosis vaccines. The company was founded by Xuan Liu, Xue Feng Yu, Tao Zhu, Dong Xu Qiu and Hui Hua Mao on January 13, 2009 and is headquartered in Tianjin, China.

LSI Medience Corp. engages in the clinical examination business. It also engages in the diagnostic agent and drug discovery support business. The company was founded on April 1, 2014 and is headquartered in Tokyo, Japan.

Jiangsu Qitian Gene Biotechnology Co., Ltd., established on 2012-08-29, Business scope includes genetic biological products,Nucleic Acid Amplification Reagents,Nucleic acid detection reagent,Veterinary biological products,Technology research and development of nucleic acid amplification detection instruments,manufacture,Sales;Detection kit(Does not contain drugs,dangerous goods),Research and development of a class of medical devices,Sales;Animal and plant disease control;computer software development,Technical Services;Socio-Economic Information Consulting Services(Does not include investment advice);Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Veterinary drug production;Veterinary drug business;Class III medical device business;Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices;Sales of Class I Medical Devices;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Wuhan Onix Gene Technology Co., Ltd., established on 2002-08-06, The scope of business includes the research and development of biological gene technology(Does not contain medicine,Health Products and Restricted Items).

Leiden University Medical Center (Dutch: Leids Universitair Medisch Centrum) or LUMC is the university hospital affiliated with Leiden University, of which it forms the medical faculty. It is located in Leiden, Netherlands. LUMC is a modern university medical center for research, education and patient care. Its research practice ranges from pure fundamental medical research to applied clinical research.

Jiaxing Anyu Biotechnology Co., Ltd., established on 2014-04-14, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Drug Wholesale;Veterinary drug production;Veterinary drug business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).